The use of knockout mice reveals a synergistic role of the vav1 and rasgrf2 gene deficiencies in lymphomagenesis and metastasis

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Ruiz, Sergio ^a,b   Santos, Eugenio ^a   Bustelo, Xosé R ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MESSENGER RNA; PROTEIN RASGRF2; PROTEIN VAV1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; HEMATOLOGIC MALIGNANCY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LARGE CELL LYMPHOMA; LATENT PERIOD; LEUKEMOGENESIS; LYMPHOBLAST; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTO ONCOGENE; THYMUS;

ANIMALS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-VAV; RAS GUANINE NUCLEOTIDE EXCHANGE FACTORS; RNA, MESSENGER; THYMUS NEOPLASMS;

ANIMALIA; MUS;

EID: 77949535231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008229     Document Type: Article

References (49)

1. Colicelli J (2004) Human RAS superfamily proteins and related GTPases. Sci STKE 2004: RE13.
2. Sahai E, Marshall CJ (2002) RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
3. Boettner B, Van Aelst L (2002) The role of Rho GTPases in disease development. Gene 286: 155-174.
4. Bar-Sagi D, Hall A (2000) Ras and Rho GTPases: a family reunion. Cell 103: 227-238.
5. Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62: 851-891.
6. Barbacid M (1987) Ras genes. Annu Rev Biochem 56: 779-827.
7. Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: critical elements in the control of small G proteins. Cell 129: 865-877.
8. Dransart E, Olofsson B, Cherfils J (2005) RhoGDIs revisited: novel roles in Rho regulation. Traffic 6: 957-966.
9. DerMardirossian C, Bokoch GM (2005) GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 15: 356-363.
10. Olofsson B (1999) Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 11: 545-554.
11. Lin Q, Fuji RN, Yang W, Cerione RA (2003) RhoGDI is required for Cdc42- mediated cellular transformation. Curr Biol 13: 1469-1479.
12. Qiu C, Yu M, Shan L, Snyderwine EG (2003) Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. On-cogene 22: 1253-1260.
13. Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, et al. (2004) Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 23: 8705-8710.
14. Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, et al. (2006) Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol Rep 15: 1281-1285.
15. Jacinto FV, Ballestar E, Ropero S, Esteller M (2007) Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 67: 11481-11486.
16. Katzav S, Martin-Zanca D, Barbacid, M (1989) Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. Embo J 8: 2283-2290.
17. Tognon CE, Kirk HE, Passmore LA, Whitehead IP, Der CJ, et al. (1998) Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol 18: 6995-7008.
18. Ruiz S, Santos E, Bustelo XR (2007) RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses. Mol Cell Biol 27: 8127-8142.
19. Moldovan GL, Pfander B, Jentsch S (2007) PCNA, the maestro of the replication fork. Cell 129: 665-679.
20. Sancho D, Gomez M, Sanchez-Madrid F (2005) CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 26: 136-140.
21. Turner M, Mee PJ, Walters AE, Quinn ME, Mellor AL, et al. (1997) A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7: 451-460.
22. Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, et al. (1995) Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374: 467-470.
23. MacDonald JW, Ghosh D (2006) COPA-cancer outlier profile analysis. Bioinformatics 22: 2950-2951.
24. Bustelo XR (2000) Regulatory and signaling properties of the Vav family. Mol Cell Biol 20: 1461-1477.
25. Tybulewicz VL, Ardouin L, Prisco A, Reynolds LF (2003) Vav1: a key signal transducer downstream of the TCR. Immunol Rev 192: 42-52.
26. Saveliev A, Tybulewicz VL (2009) Lymphocyte signaling: beyond knockouts. Nat Immunol 10: 361-364.
27. Dumont C, Corsoni-Tadrzak A, Ruf, S, de Boer J, Williams A, et al. (2008) Rac GTPases play critical roles in early T cell development. Blood.
28. Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6: 347-359.
29. Cleverley SC, Costello PS, Henning SW, Cantrell DA (2000) Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 19: 13-20.
30. Prieto-Sanchez RM, Hernandez JA, Garcia JL, Gutierrez NC, San Miguel J, et al. (2006) Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. Br J Haematol 133: 642-645.
31. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, et al. (2005) Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7: 39-49.
32. Dong Z, Liu Y, Lu S, Wang A, Lee K, et al. (2006) Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 20: 2315-2325.
33. Lyons LS, Burnstein KL (2006) Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 20: 1061-1072.
34. Lee K, Liu Y, Mo JQ, Zhang J, Dong Z, et al. (2008) Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 8: 158.
35. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC (2005) Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613.
36. Doody GM, Bell SE, Vigorito E, Clayton E, McAdam S, et al. (2001) Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation. Nat Immunol 2: 542-547.
37. Sauzeau V, Jerkic M, Lopez-Novoa JM, Bustelo XR (2007) Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 18: 943-952.
38. Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, et al. (2006) Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 12: 841-845.
39. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647.
40. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, et al. (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 22: 3937-3949.
41. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, et al. (2007) Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109: 1692-1700.
42. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390.
43. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
44. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, et al. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113: 3088-3091.
45. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431-2442.
46. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, et al. (2008) An 86-probe-set gene-expression signature predicts survival in cytoge- netically normal acute myeloid leukemia. Blood 112: 4193-4201.
47. Radich JP, Dai H, Mao M, Oehler V, Schelter J, et al. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103: 2794-2799.
48. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, et al. (2003) Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102: 2951-2959.
49. Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, et al. (2008) Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol 26: 4376-4384.